nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—EPHA5—cerebellum—attention deficit hyperactivity disorder	0.00128	0.00226	CbGeAlD
Bosutinib—ERBB4—nervous system—attention deficit hyperactivity disorder	0.00127	0.00224	CbGeAlD
Bosutinib—CSNK1E—midbrain—attention deficit hyperactivity disorder	0.00126	0.00222	CbGeAlD
Bosutinib—TNK2—central nervous system—attention deficit hyperactivity disorder	0.00126	0.00222	CbGeAlD
Bosutinib—ROCK1—nervous system—attention deficit hyperactivity disorder	0.00126	0.00221	CbGeAlD
Bosutinib—CHEK2—brain—attention deficit hyperactivity disorder	0.00125	0.0022	CbGeAlD
Bosutinib—CSF1R—forebrain—attention deficit hyperactivity disorder	0.00124	0.00219	CbGeAlD
Bosutinib—DMPK—brain—attention deficit hyperactivity disorder	0.00124	0.00219	CbGeAlD
Bosutinib—WEE1—brain—attention deficit hyperactivity disorder	0.00124	0.00219	CbGeAlD
Bosutinib—TNK2—cerebellum—attention deficit hyperactivity disorder	0.00123	0.00217	CbGeAlD
Bosutinib—ERBB4—central nervous system—attention deficit hyperactivity disorder	0.00123	0.00216	CbGeAlD
Bosutinib—BMPR2—nervous system—attention deficit hyperactivity disorder	0.00122	0.00215	CbGeAlD
Bosutinib—ERBB3—midbrain—attention deficit hyperactivity disorder	0.00122	0.00215	CbGeAlD
Bosutinib—MAP2K2—midbrain—attention deficit hyperactivity disorder	0.00122	0.00214	CbGeAlD
Bosutinib—ULK3—midbrain—attention deficit hyperactivity disorder	0.00122	0.00214	CbGeAlD
Bosutinib—MAP4K2—cerebellum—attention deficit hyperactivity disorder	0.00121	0.00214	CbGeAlD
Bosutinib—STK36—nervous system—attention deficit hyperactivity disorder	0.00121	0.00213	CbGeAlD
Bosutinib—EPHB3—nervous system—attention deficit hyperactivity disorder	0.00121	0.00213	CbGeAlD
Bosutinib—ROCK1—central nervous system—attention deficit hyperactivity disorder	0.00121	0.00213	CbGeAlD
Bosutinib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.00121	0.00212	CbGeAlD
Bosutinib—TAOK3—cardiovascular system—attention deficit hyperactivity disorder	0.0012	0.00212	CbGeAlD
Bosutinib—ERBB4—cerebellum—attention deficit hyperactivity disorder	0.0012	0.00211	CbGeAlD
Bosutinib—STK3—cerebellum—attention deficit hyperactivity disorder	0.0012	0.00211	CbGeAlD
Bosutinib—MERTK—nervous system—attention deficit hyperactivity disorder	0.0012	0.00211	CbGeAlD
Bosutinib—MAP3K7—midbrain—attention deficit hyperactivity disorder	0.0012	0.00211	CbGeAlD
Bosutinib—STK25—brain—attention deficit hyperactivity disorder	0.00119	0.00209	CbGeAlD
Bosutinib—PTK2—midbrain—attention deficit hyperactivity disorder	0.00118	0.00208	CbGeAlD
Bosutinib—TBK1—midbrain—attention deficit hyperactivity disorder	0.00118	0.00208	CbGeAlD
Bosutinib—EPHA3—brain—attention deficit hyperactivity disorder	0.00118	0.00207	CbGeAlD
Bosutinib—BMPR2—central nervous system—attention deficit hyperactivity disorder	0.00118	0.00207	CbGeAlD
Bosutinib—MAP4K4—nervous system—attention deficit hyperactivity disorder	0.00118	0.00207	CbGeAlD
Bosutinib—SRC—cardiovascular system—attention deficit hyperactivity disorder	0.00117	0.00206	CbGeAlD
Bosutinib—BCR—nervous system—attention deficit hyperactivity disorder	0.00117	0.00205	CbGeAlD
Bosutinib—STK36—central nervous system—attention deficit hyperactivity disorder	0.00117	0.00205	CbGeAlD
Bosutinib—EPHB3—central nervous system—attention deficit hyperactivity disorder	0.00117	0.00205	CbGeAlD
Bosutinib—IRAK1—midbrain—attention deficit hyperactivity disorder	0.00116	0.00204	CbGeAlD
Bosutinib—MAP3K12—nervous system—attention deficit hyperactivity disorder	0.00116	0.00204	CbGeAlD
Bosutinib—MERTK—central nervous system—attention deficit hyperactivity disorder	0.00115	0.00203	CbGeAlD
Bosutinib—PLK2—brain—attention deficit hyperactivity disorder	0.00115	0.00203	CbGeAlD
Bosutinib—BMPR2—cerebellum—attention deficit hyperactivity disorder	0.00115	0.00202	CbGeAlD
Bosutinib—SIK3—brain—attention deficit hyperactivity disorder	0.00114	0.00202	CbGeAlD
Bosutinib—STK36—cerebellum—attention deficit hyperactivity disorder	0.00114	0.00201	CbGeAlD
Bosutinib—EPHB3—cerebellum—attention deficit hyperactivity disorder	0.00114	0.00201	CbGeAlD
Bosutinib—RPS6KB1—midbrain—attention deficit hyperactivity disorder	0.00114	0.002	CbGeAlD
Bosutinib—MAP2K1—nervous system—attention deficit hyperactivity disorder	0.00113	0.002	CbGeAlD
Bosutinib—STK35—nervous system—attention deficit hyperactivity disorder	0.00113	0.002	CbGeAlD
Bosutinib—MAP4K4—central nervous system—attention deficit hyperactivity disorder	0.00113	0.00199	CbGeAlD
Bosutinib—CSK—nervous system—attention deficit hyperactivity disorder	0.00113	0.00199	CbGeAlD
Bosutinib—MERTK—cerebellum—attention deficit hyperactivity disorder	0.00113	0.00198	CbGeAlD
Bosutinib—AXL—midbrain—attention deficit hyperactivity disorder	0.00113	0.00198	CbGeAlD
Bosutinib—BCR—central nervous system—attention deficit hyperactivity disorder	0.00112	0.00198	CbGeAlD
Bosutinib—CSNK1A1—nervous system—attention deficit hyperactivity disorder	0.00112	0.00197	CbGeAlD
Bosutinib—MAP3K12—central nervous system—attention deficit hyperactivity disorder	0.00112	0.00196	CbGeAlD
Bosutinib—HCK—nervous system—attention deficit hyperactivity disorder	0.00111	0.00196	CbGeAlD
Bosutinib—CLK1—nervous system—attention deficit hyperactivity disorder	0.00111	0.00196	CbGeAlD
Bosutinib—MAP4K4—cerebellum—attention deficit hyperactivity disorder	0.00111	0.00195	CbGeAlD
Bosutinib—STK4—brain—attention deficit hyperactivity disorder	0.0011	0.00194	CbGeAlD
Bosutinib—NUAK2—cerebellum—attention deficit hyperactivity disorder	0.0011	0.00193	CbGeAlD
Bosutinib—BCR—cerebellum—attention deficit hyperactivity disorder	0.0011	0.00193	CbGeAlD
Bosutinib—MAP2K1—central nervous system—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—STK35—central nervous system—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—BMP2K—nervous system—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—CAMK2G—nervous system—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—MAP3K12—cerebellum—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—CAMK1D—brain—attention deficit hyperactivity disorder	0.00109	0.00192	CbGeAlD
Bosutinib—CSK—central nervous system—attention deficit hyperactivity disorder	0.00109	0.00191	CbGeAlD
Bosutinib—SLK—midbrain—attention deficit hyperactivity disorder	0.00108	0.00191	CbGeAlD
Bosutinib—LRRK2—nervous system—attention deficit hyperactivity disorder	0.00108	0.00191	CbGeAlD
Bosutinib—CSNK1A1—central nervous system—attention deficit hyperactivity disorder	0.00108	0.0019	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.00108	0.0019	CbGeAlD
Bosutinib—STK24—brain—attention deficit hyperactivity disorder	0.00108	0.0019	CbGeAlD
Bosutinib—EPHB4—midbrain—attention deficit hyperactivity disorder	0.00108	0.00189	CbGeAlD
Bosutinib—HCK—central nervous system—attention deficit hyperactivity disorder	0.00107	0.00189	CbGeAlD
Bosutinib—CLK1—central nervous system—attention deficit hyperactivity disorder	0.00107	0.00189	CbGeAlD
Bosutinib—MAP2K1—cerebellum—attention deficit hyperactivity disorder	0.00107	0.00188	CbGeAlD
Bosutinib—STK35—cerebellum—attention deficit hyperactivity disorder	0.00107	0.00188	CbGeAlD
Bosutinib—CSK—cerebellum—attention deficit hyperactivity disorder	0.00106	0.00187	CbGeAlD
Bosutinib—PTK2B—nervous system—attention deficit hyperactivity disorder	0.00106	0.00186	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—attention deficit hyperactivity disorder	0.00105	0.00186	CbGeAlD
Bosutinib—FYN—midbrain—attention deficit hyperactivity disorder	0.00105	0.00186	CbGeAlD
Bosutinib—CAMK2G—central nervous system—attention deficit hyperactivity disorder	0.00105	0.00185	CbGeAlD
Bosutinib—BMP2K—central nervous system—attention deficit hyperactivity disorder	0.00105	0.00185	CbGeAlD
Bosutinib—CSF1R—cardiovascular system—attention deficit hyperactivity disorder	0.00105	0.00185	CbGeAlD
Bosutinib—CLK1—cerebellum—attention deficit hyperactivity disorder	0.00105	0.00184	CbGeAlD
Bosutinib—LRRK2—central nervous system—attention deficit hyperactivity disorder	0.00104	0.00184	CbGeAlD
Bosutinib—EPHA5—brain—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—ALK—brain—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—FER—brain—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—TYRO3—brain—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—ABL2—cerebellum—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—CSNK1E—nervous system—attention deficit hyperactivity disorder	0.00104	0.00183	CbGeAlD
Bosutinib—LYN—brain—attention deficit hyperactivity disorder	0.00104	0.00182	CbGeAlD
Bosutinib—MAP3K3—midbrain—attention deficit hyperactivity disorder	0.00103	0.00181	CbGeAlD
Bosutinib—MAP4K5—midbrain—attention deficit hyperactivity disorder	0.00103	0.00181	CbGeAlD
Bosutinib—CAMK2G—cerebellum—attention deficit hyperactivity disorder	0.00103	0.00181	CbGeAlD
Bosutinib—BMP2K—cerebellum—attention deficit hyperactivity disorder	0.00103	0.00181	CbGeAlD
Bosutinib—SIK1—nervous system—attention deficit hyperactivity disorder	0.00102	0.0018	CbGeAlD
Bosutinib—IRAK4—nervous system—attention deficit hyperactivity disorder	0.00102	0.0018	CbGeAlD
Bosutinib—MAP4K1—brain—attention deficit hyperactivity disorder	0.00102	0.0018	CbGeAlD
Bosutinib—MAP3K19—brain—attention deficit hyperactivity disorder	0.00102	0.0018	CbGeAlD
Bosutinib—LRRK2—cerebellum—attention deficit hyperactivity disorder	0.00102	0.00179	CbGeAlD
Bosutinib—EGFR—cerebellum—attention deficit hyperactivity disorder	0.00102	0.00179	CbGeAlD
Bosutinib—PTK2B—central nervous system—attention deficit hyperactivity disorder	0.00102	0.00179	CbGeAlD
Bosutinib—BTK—brain—attention deficit hyperactivity disorder	0.00102	0.00179	CbGeAlD
Bosutinib—EPHA4—nervous system—attention deficit hyperactivity disorder	0.00101	0.00178	CbGeAlD
Bosutinib—ERBB3—nervous system—attention deficit hyperactivity disorder	0.001	0.00176	CbGeAlD
Bosutinib—TNK2—brain—attention deficit hyperactivity disorder	0.001	0.00176	CbGeAlD
Bosutinib—CSNK1E—central nervous system—attention deficit hyperactivity disorder	0.000999	0.00176	CbGeAlD
Bosutinib—MAP2K2—nervous system—attention deficit hyperactivity disorder	0.000999	0.00176	CbGeAlD
Bosutinib—ULK3—nervous system—attention deficit hyperactivity disorder	0.000999	0.00176	CbGeAlD
Bosutinib—PTK2B—cerebellum—attention deficit hyperactivity disorder	0.000993	0.00175	CbGeAlD
Bosutinib—MAP3K2—nervous system—attention deficit hyperactivity disorder	0.000992	0.00175	CbGeAlD
Bosutinib—MAP4K2—brain—attention deficit hyperactivity disorder	0.000987	0.00174	CbGeAlD
Bosutinib—IRAK4—central nervous system—attention deficit hyperactivity disorder	0.000984	0.00173	CbGeAlD
Bosutinib—SIK1—central nervous system—attention deficit hyperactivity disorder	0.000984	0.00173	CbGeAlD
Bosutinib—CSNK1E—cerebellum—attention deficit hyperactivity disorder	0.000977	0.00172	CbGeAlD
Bosutinib—EPHA4—central nervous system—attention deficit hyperactivity disorder	0.000974	0.00172	CbGeAlD
Bosutinib—ERBB4—brain—attention deficit hyperactivity disorder	0.000973	0.00171	CbGeAlD
Bosutinib—STK3—brain—attention deficit hyperactivity disorder	0.000973	0.00171	CbGeAlD
Bosutinib—PTK2—nervous system—attention deficit hyperactivity disorder	0.000972	0.00171	CbGeAlD
Bosutinib—TBK1—nervous system—attention deficit hyperactivity disorder	0.000972	0.00171	CbGeAlD
Bosutinib—ERBB3—central nervous system—attention deficit hyperactivity disorder	0.000964	0.0017	CbGeAlD
Bosutinib—ULK3—central nervous system—attention deficit hyperactivity disorder	0.000962	0.00169	CbGeAlD
Bosutinib—MAP2K2—central nervous system—attention deficit hyperactivity disorder	0.000962	0.00169	CbGeAlD
Bosutinib—IRAK4—cerebellum—attention deficit hyperactivity disorder	0.000962	0.00169	CbGeAlD
Bosutinib—SIK1—cerebellum—attention deficit hyperactivity disorder	0.000962	0.00169	CbGeAlD
Bosutinib—ROCK1—brain—attention deficit hyperactivity disorder	0.000961	0.00169	CbGeAlD
Bosutinib—MAP3K2—central nervous system—attention deficit hyperactivity disorder	0.000955	0.00168	CbGeAlD
Bosutinib—EPHA4—cerebellum—attention deficit hyperactivity disorder	0.000952	0.00168	CbGeAlD
Bosutinib—YES1—midbrain—attention deficit hyperactivity disorder	0.000951	0.00167	CbGeAlD
Bosutinib—ERBB3—cerebellum—attention deficit hyperactivity disorder	0.000943	0.00166	CbGeAlD
Bosutinib—MAP2K2—cerebellum—attention deficit hyperactivity disorder	0.00094	0.00166	CbGeAlD
Bosutinib—ULK3—cerebellum—attention deficit hyperactivity disorder	0.00094	0.00166	CbGeAlD
Bosutinib—TAOK3—midbrain—attention deficit hyperactivity disorder	0.000938	0.00165	CbGeAlD
Bosutinib—PTK2—central nervous system—attention deficit hyperactivity disorder	0.000935	0.00165	CbGeAlD
Bosutinib—TBK1—central nervous system—attention deficit hyperactivity disorder	0.000935	0.00165	CbGeAlD
Bosutinib—RPS6KB1—nervous system—attention deficit hyperactivity disorder	0.000935	0.00165	CbGeAlD
Bosutinib—MAP3K2—cerebellum—attention deficit hyperactivity disorder	0.000934	0.00164	CbGeAlD
Bosutinib—BMPR2—brain—attention deficit hyperactivity disorder	0.000933	0.00164	CbGeAlD
Bosutinib—PDGFRB—cardiovascular system—attention deficit hyperactivity disorder	0.000932	0.00164	CbGeAlD
Bosutinib—FGR—nervous system—attention deficit hyperactivity disorder	0.000929	0.00164	CbGeAlD
Bosutinib—STK36—brain—attention deficit hyperactivity disorder	0.000926	0.00163	CbGeAlD
Bosutinib—EPHB3—brain—attention deficit hyperactivity disorder	0.000926	0.00163	CbGeAlD
Bosutinib—AXL—nervous system—attention deficit hyperactivity disorder	0.000925	0.00163	CbGeAlD
Bosutinib—MAP3K7—cerebellum—attention deficit hyperactivity disorder	0.000925	0.00163	CbGeAlD
Bosutinib—MERTK—brain—attention deficit hyperactivity disorder	0.000915	0.00161	CbGeAlD
Bosutinib—TBK1—cerebellum—attention deficit hyperactivity disorder	0.000914	0.00161	CbGeAlD
Bosutinib—PTK2—cerebellum—attention deficit hyperactivity disorder	0.000914	0.00161	CbGeAlD
Bosutinib—RPS6KB1—central nervous system—attention deficit hyperactivity disorder	0.0009	0.00158	CbGeAlD
Bosutinib—MAP4K4—brain—attention deficit hyperactivity disorder	0.000898	0.00158	CbGeAlD
Bosutinib—IRAK1—cerebellum—attention deficit hyperactivity disorder	0.000896	0.00158	CbGeAlD
Bosutinib—FGR—central nervous system—attention deficit hyperactivity disorder	0.000894	0.00158	CbGeAlD
Bosutinib—NUAK2—brain—attention deficit hyperactivity disorder	0.000892	0.00157	CbGeAlD
Bosutinib—BCR—brain—attention deficit hyperactivity disorder	0.000892	0.00157	CbGeAlD
Bosutinib—AXL—central nervous system—attention deficit hyperactivity disorder	0.000891	0.00157	CbGeAlD
Bosutinib—MAP3K12—brain—attention deficit hyperactivity disorder	0.000885	0.00156	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—attention deficit hyperactivity disorder	0.000879	0.00155	CbGeAlD
Bosutinib—AXL—cerebellum—attention deficit hyperactivity disorder	0.000871	0.00153	CbGeAlD
Bosutinib—MAP2K1—brain—attention deficit hyperactivity disorder	0.000868	0.00153	CbGeAlD
Bosutinib—STK35—brain—attention deficit hyperactivity disorder	0.000868	0.00153	CbGeAlD
Bosutinib—EPHA2—nervous system—attention deficit hyperactivity disorder	0.000867	0.00153	CbGeAlD
Bosutinib—FYN—nervous system—attention deficit hyperactivity disorder	0.000866	0.00153	CbGeAlD
Bosutinib—CSK—brain—attention deficit hyperactivity disorder	0.000862	0.00152	CbGeAlD
Bosutinib—CSNK1A1—brain—attention deficit hyperactivity disorder	0.000856	0.00151	CbGeAlD
Bosutinib—HCK—brain—attention deficit hyperactivity disorder	0.000851	0.0015	CbGeAlD
Bosutinib—CLK1—brain—attention deficit hyperactivity disorder	0.000851	0.0015	CbGeAlD
Bosutinib—MAP4K5—nervous system—attention deficit hyperactivity disorder	0.000846	0.00149	CbGeAlD
Bosutinib—MAP3K3—nervous system—attention deficit hyperactivity disorder	0.000846	0.00149	CbGeAlD
Bosutinib—ABL2—brain—attention deficit hyperactivity disorder	0.000845	0.00149	CbGeAlD
Bosutinib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.000841	0.00148	CbGeAlD
Bosutinib—SLK—cerebellum—attention deficit hyperactivity disorder	0.000838	0.00148	CbGeAlD
Bosutinib—EPHA2—central nervous system—attention deficit hyperactivity disorder	0.000835	0.00147	CbGeAlD
Bosutinib—CAMK2G—brain—attention deficit hyperactivity disorder	0.000835	0.00147	CbGeAlD
Bosutinib—BMP2K—brain—attention deficit hyperactivity disorder	0.000835	0.00147	CbGeAlD
Bosutinib—FYN—central nervous system—attention deficit hyperactivity disorder	0.000834	0.00147	CbGeAlD
Bosutinib—EPHB4—cerebellum—attention deficit hyperactivity disorder	0.000832	0.00147	CbGeAlD
Bosutinib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.000831	0.00146	CbGeAlD
Bosutinib—LRRK2—brain—attention deficit hyperactivity disorder	0.000828	0.00146	CbGeAlD
Bosutinib—EGFR—brain—attention deficit hyperactivity disorder	0.000825	0.00145	CbGeAlD
Bosutinib—CSF1R—midbrain—attention deficit hyperactivity disorder	0.000821	0.00145	CbGeAlD
Bosutinib—FYN—cerebellum—attention deficit hyperactivity disorder	0.000815	0.00144	CbGeAlD
Bosutinib—MAP4K5—central nervous system—attention deficit hyperactivity disorder	0.000815	0.00143	CbGeAlD
Bosutinib—MAP3K3—central nervous system—attention deficit hyperactivity disorder	0.000815	0.00143	CbGeAlD
Bosutinib—PTK2B—brain—attention deficit hyperactivity disorder	0.000806	0.00142	CbGeAlD
Bosutinib—MAP3K3—cerebellum—attention deficit hyperactivity disorder	0.000796	0.0014	CbGeAlD
Bosutinib—MAP4K5—cerebellum—attention deficit hyperactivity disorder	0.000796	0.0014	CbGeAlD
Bosutinib—CSNK1E—brain—attention deficit hyperactivity disorder	0.000793	0.0014	CbGeAlD
Bosutinib—YES1—nervous system—attention deficit hyperactivity disorder	0.000781	0.00138	CbGeAlD
Bosutinib—SIK1—brain—attention deficit hyperactivity disorder	0.000781	0.00138	CbGeAlD
Bosutinib—IRAK4—brain—attention deficit hyperactivity disorder	0.000781	0.00138	CbGeAlD
Bosutinib—STK10—nervous system—attention deficit hyperactivity disorder	0.000774	0.00136	CbGeAlD
Bosutinib—EPHA4—brain—attention deficit hyperactivity disorder	0.000773	0.00136	CbGeAlD
Bosutinib—TAOK3—nervous system—attention deficit hyperactivity disorder	0.000771	0.00136	CbGeAlD
Bosutinib—ERBB3—brain—attention deficit hyperactivity disorder	0.000766	0.00135	CbGeAlD
Bosutinib—ULK3—brain—attention deficit hyperactivity disorder	0.000764	0.00135	CbGeAlD
Bosutinib—MAP2K2—brain—attention deficit hyperactivity disorder	0.000764	0.00135	CbGeAlD
Bosutinib—MAP3K2—brain—attention deficit hyperactivity disorder	0.000758	0.00134	CbGeAlD
Bosutinib—YES1—central nervous system—attention deficit hyperactivity disorder	0.000752	0.00133	CbGeAlD
Bosutinib—SRC—nervous system—attention deficit hyperactivity disorder	0.000752	0.00132	CbGeAlD
Bosutinib—MAP3K7—brain—attention deficit hyperactivity disorder	0.000751	0.00132	CbGeAlD
Bosutinib—STK10—central nervous system—attention deficit hyperactivity disorder	0.000746	0.00131	CbGeAlD
Bosutinib—TAOK3—central nervous system—attention deficit hyperactivity disorder	0.000743	0.00131	CbGeAlD
Bosutinib—TBK1—brain—attention deficit hyperactivity disorder	0.000743	0.00131	CbGeAlD
Bosutinib—PTK2—brain—attention deficit hyperactivity disorder	0.000743	0.00131	CbGeAlD
Bosutinib—YES1—cerebellum—attention deficit hyperactivity disorder	0.000735	0.0013	CbGeAlD
Bosutinib—STK10—cerebellum—attention deficit hyperactivity disorder	0.000729	0.00128	CbGeAlD
Bosutinib—PDGFRB—midbrain—attention deficit hyperactivity disorder	0.000728	0.00128	CbGeAlD
Bosutinib—IRAK1—brain—attention deficit hyperactivity disorder	0.000728	0.00128	CbGeAlD
Bosutinib—TAOK3—cerebellum—attention deficit hyperactivity disorder	0.000726	0.00128	CbGeAlD
Bosutinib—SRC—central nervous system—attention deficit hyperactivity disorder	0.000724	0.00127	CbGeAlD
Bosutinib—RPS6KB1—brain—attention deficit hyperactivity disorder	0.000714	0.00126	CbGeAlD
Bosutinib—FGR—brain—attention deficit hyperactivity disorder	0.00071	0.00125	CbGeAlD
Bosutinib—SRC—cerebellum—attention deficit hyperactivity disorder	0.000707	0.00125	CbGeAlD
Bosutinib—AXL—brain—attention deficit hyperactivity disorder	0.000707	0.00125	CbGeAlD
Bosutinib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.000692	0.00122	CbGeAlD
Bosutinib—SLK—brain—attention deficit hyperactivity disorder	0.000681	0.0012	CbGeAlD
Bosutinib—EPHB4—brain—attention deficit hyperactivity disorder	0.000676	0.00119	CbGeAlD
Bosutinib—CSF1R—nervous system—attention deficit hyperactivity disorder	0.000675	0.00119	CbGeAlD
Bosutinib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.000666	0.00117	CbGeAlD
Bosutinib—EPHA2—brain—attention deficit hyperactivity disorder	0.000663	0.00117	CbGeAlD
Bosutinib—FYN—brain—attention deficit hyperactivity disorder	0.000662	0.00117	CbGeAlD
Bosutinib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.000651	0.00115	CbGeAlD
Bosutinib—CSF1R—central nervous system—attention deficit hyperactivity disorder	0.00065	0.00114	CbGeAlD
Bosutinib—ABL1—midbrain—attention deficit hyperactivity disorder	0.000649	0.00114	CbGeAlD
Bosutinib—MAP3K3—brain—attention deficit hyperactivity disorder	0.000647	0.00114	CbGeAlD
Bosutinib—MAP4K5—brain—attention deficit hyperactivity disorder	0.000647	0.00114	CbGeAlD
Bosutinib—CSF1R—cerebellum—attention deficit hyperactivity disorder	0.000635	0.00112	CbGeAlD
Bosutinib—PDGFRB—nervous system—attention deficit hyperactivity disorder	0.000599	0.00105	CbGeAlD
Bosutinib—YES1—brain—attention deficit hyperactivity disorder	0.000597	0.00105	CbGeAlD
Bosutinib—STK10—brain—attention deficit hyperactivity disorder	0.000592	0.00104	CbGeAlD
Bosutinib—TAOK3—brain—attention deficit hyperactivity disorder	0.00059	0.00104	CbGeAlD
Bosutinib—PDGFRB—central nervous system—attention deficit hyperactivity disorder	0.000576	0.00102	CbGeAlD
Bosutinib—SRC—brain—attention deficit hyperactivity disorder	0.000575	0.00101	CbGeAlD
Bosutinib—PDGFRB—cerebellum—attention deficit hyperactivity disorder	0.000563	0.000992	CbGeAlD
Bosutinib—ABL1—nervous system—attention deficit hyperactivity disorder	0.000534	0.00094	CbGeAlD
Bosutinib—MAP2K5—brain—attention deficit hyperactivity disorder	0.000529	0.000931	CbGeAlD
Bosutinib—CSF1R—brain—attention deficit hyperactivity disorder	0.000516	0.000909	CbGeAlD
Bosutinib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.000514	0.000905	CbGeAlD
Bosutinib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.000502	0.000884	CbGeAlD
Bosutinib—PDGFRB—brain—attention deficit hyperactivity disorder	0.000458	0.000806	CbGeAlD
Bosutinib—ABL1—brain—attention deficit hyperactivity disorder	0.000408	0.000718	CbGeAlD
Bosutinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000306	0.000538	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000258	0.000455	CbGeAlD
Bosutinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000234	0.000413	CbGeAlD
Bosutinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000226	0.000397	CbGeAlD
Bosutinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000202	0.000355	CbGeAlD
Bosutinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000166	0.000292	CbGeAlD
Bosutinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00016	0.000281	CbGeAlD
Bosutinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000156	0.000275	CbGeAlD
Bosutinib—ABCB1—brain—attention deficit hyperactivity disorder	0.000127	0.000223	CbGeAlD
Bosutinib—PDGFRB—Disease—SNAP25—attention deficit hyperactivity disorder	5.51e-05	0.000128	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.5e-05	0.000127	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.5e-05	0.000127	CbGpPWpGaD
Bosutinib—IKBKE—Immune System—EP300—attention deficit hyperactivity disorder	5.5e-05	0.000127	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.49e-05	0.000127	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.45e-05	0.000126	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.45e-05	0.000126	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.44e-05	0.000126	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.43e-05	0.000126	CbGpPWpGaD
Bosutinib—FGR—Innate Immune System—EP300—attention deficit hyperactivity disorder	5.42e-05	0.000125	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.39e-05	0.000125	CbGpPWpGaD
Bosutinib—FYN—Disease—SNAP25—attention deficit hyperactivity disorder	5.31e-05	0.000123	CbGpPWpGaD
Bosutinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.3e-05	0.000123	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—SNAP25—attention deficit hyperactivity disorder	5.29e-05	0.000122	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.27e-05	0.000122	CbGpPWpGaD
Bosutinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.26e-05	0.000122	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.25e-05	0.000121	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.25e-05	0.000121	CbGpPWpGaD
Bosutinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.23e-05	0.000121	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.18e-05	0.00012	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.17e-05	0.00012	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.14e-05	0.000119	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.12e-05	0.000118	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.07e-05	0.000117	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.06e-05	0.000117	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—EP300—attention deficit hyperactivity disorder	5.02e-05	0.000116	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.98e-05	0.000115	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.98e-05	0.000115	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.97e-05	0.000115	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—EP300—attention deficit hyperactivity disorder	4.95e-05	0.000115	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—EP300—attention deficit hyperactivity disorder	4.93e-05	0.000114	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.91e-05	0.000114	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.89e-05	0.000113	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.87e-05	0.000113	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.87e-05	0.000113	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.87e-05	0.000113	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—EP300—attention deficit hyperactivity disorder	4.86e-05	0.000112	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.83e-05	0.000112	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.83e-05	0.000112	CbGpPWpGaD
Bosutinib—FER—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.82e-05	0.000112	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.81e-05	0.000111	CbGpPWpGaD
Bosutinib—SYK—Immune System—EP300—attention deficit hyperactivity disorder	4.8e-05	0.000111	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.77e-05	0.00011	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.77e-05	0.00011	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.77e-05	0.00011	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.75e-05	0.00011	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—EP300—attention deficit hyperactivity disorder	4.72e-05	0.000109	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.66e-05	0.000108	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.65e-05	0.000108	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.65e-05	0.000108	CbGpPWpGaD
Bosutinib—EGFR—Disease—SNAP25—attention deficit hyperactivity disorder	4.59e-05	0.000106	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.58e-05	0.000106	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.58e-05	0.000106	CbGpPWpGaD
Bosutinib—AXL—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.57e-05	0.000106	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.55e-05	0.000105	CbGpPWpGaD
Bosutinib—CSK—Immune System—EP300—attention deficit hyperactivity disorder	4.55e-05	0.000105	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.53e-05	0.000105	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.52e-05	0.000105	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.5e-05	0.000104	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.44e-05	0.000103	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.44e-05	0.000103	CbGpPWpGaD
Bosutinib—LCK—Disease—SNAP25—attention deficit hyperactivity disorder	4.42e-05	0.000102	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.38e-05	0.000101	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.37e-05	0.000101	CbGpPWpGaD
Bosutinib—BMPR2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.36e-05	0.000101	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—EP300—attention deficit hyperactivity disorder	4.35e-05	0.000101	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—EP300—attention deficit hyperactivity disorder	4.35e-05	0.000101	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.31e-05	9.97e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.26e-05	9.85e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.26e-05	9.84e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.21e-05	9.74e-05	CbGpPWpGaD
Bosutinib—CSK—Disease—EP300—attention deficit hyperactivity disorder	4.2e-05	9.73e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.18e-05	9.67e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.15e-05	9.61e-05	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—EP300—attention deficit hyperactivity disorder	4.15e-05	9.6e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.11e-05	9.5e-05	CbGpPWpGaD
Bosutinib—TBK1—Immune System—EP300—attention deficit hyperactivity disorder	4.08e-05	9.45e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.07e-05	9.41e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.02e-05	9.3e-05	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—EP300—attention deficit hyperactivity disorder	4.01e-05	9.28e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4e-05	9.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.98e-05	9.21e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.96e-05	9.17e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.96e-05	9.16e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.96e-05	9.15e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.96e-05	9.15e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—SNAP25—attention deficit hyperactivity disorder	3.92e-05	9.06e-05	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—EP300—attention deficit hyperactivity disorder	3.92e-05	9.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.91e-05	9.04e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.87e-05	8.94e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.86e-05	8.93e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.84e-05	8.89e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.83e-05	8.86e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.81e-05	8.82e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.81e-05	8.82e-05	CbGpPWpGaD
Bosutinib—BTK—Immune System—EP300—attention deficit hyperactivity disorder	3.81e-05	8.81e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.78e-05	8.74e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.77e-05	8.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.74e-05	8.65e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.72e-05	8.61e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.72e-05	8.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.7e-05	8.56e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.69e-05	8.55e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	3.69e-05	8.54e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.68e-05	8.51e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.67e-05	8.5e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.67e-05	8.5e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.67e-05	8.5e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.66e-05	8.47e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.65e-05	8.45e-05	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—EP300—attention deficit hyperactivity disorder	3.64e-05	8.42e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.64e-05	8.41e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.63e-05	8.4e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—EP300—attention deficit hyperactivity disorder	3.62e-05	8.38e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.62e-05	8.37e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	3.61e-05	8.34e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.6e-05	8.34e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.6e-05	8.32e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.58e-05	8.29e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—EP300—attention deficit hyperactivity disorder	3.57e-05	8.25e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.55e-05	8.22e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.54e-05	8.2e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.54e-05	8.2e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.52e-05	8.15e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—EP300—attention deficit hyperactivity disorder	3.52e-05	8.14e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.52e-05	8.14e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.5e-05	8.09e-05	CbGpPWpGaD
Bosutinib—HCK—Immune System—EP300—attention deficit hyperactivity disorder	3.5e-05	8.09e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.48e-05	8.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.46e-05	8.02e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.46e-05	8e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.41e-05	7.9e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	3.39e-05	7.85e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.38e-05	7.82e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.37e-05	7.81e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.34e-05	7.72e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.33e-05	7.71e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.33e-05	7.71e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.31e-05	7.66e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—EP300—attention deficit hyperactivity disorder	3.29e-05	7.62e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.26e-05	7.55e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.26e-05	7.54e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.25e-05	7.51e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EP300—attention deficit hyperactivity disorder	3.24e-05	7.51e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.24e-05	7.5e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—EP300—attention deficit hyperactivity disorder	3.23e-05	7.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.21e-05	7.44e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.21e-05	7.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—EP300—attention deficit hyperactivity disorder	3.19e-05	7.39e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—EP300—attention deficit hyperactivity disorder	3.17e-05	7.33e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—EP300—attention deficit hyperactivity disorder	3.16e-05	7.3e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.15e-05	7.29e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—EP300—attention deficit hyperactivity disorder	3.14e-05	7.27e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.11e-05	7.2e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.11e-05	7.19e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.11e-05	7.19e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.1e-05	7.17e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.06e-05	7.08e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.05e-05	7.05e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.05e-05	7.05e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—EP300—attention deficit hyperactivity disorder	3.04e-05	7.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.02e-05	6.99e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3e-05	6.94e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—EP300—attention deficit hyperactivity disorder	2.97e-05	6.87e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.95e-05	6.83e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.95e-05	6.82e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.95e-05	6.82e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.94e-05	6.81e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.91e-05	6.74e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EP300—attention deficit hyperactivity disorder	2.9e-05	6.72e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.82e-05	6.51e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.78e-05	6.42e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.77e-05	6.42e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.74e-05	6.35e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.71e-05	6.28e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—EP300—attention deficit hyperactivity disorder	2.68e-05	6.2e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—EP300—attention deficit hyperactivity disorder	2.68e-05	6.2e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.67e-05	6.19e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.66e-05	6.15e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—EP300—attention deficit hyperactivity disorder	2.63e-05	6.08e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.61e-05	6.04e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EP300—attention deficit hyperactivity disorder	2.58e-05	5.98e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.58e-05	5.97e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—EP300—attention deficit hyperactivity disorder	2.55e-05	5.89e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.46e-05	5.7e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.43e-05	5.62e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.43e-05	5.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.43e-05	5.61e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EP300—attention deficit hyperactivity disorder	2.42e-05	5.59e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.4e-05	5.56e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.39e-05	5.52e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.37e-05	5.48e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EP300—attention deficit hyperactivity disorder	2.37e-05	5.48e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.32e-05	5.36e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.28e-05	5.28e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EP300—attention deficit hyperactivity disorder	2.28e-05	5.26e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.27e-05	5.25e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.22e-05	5.14e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.17e-05	5.01e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.13e-05	4.93e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.1e-05	4.85e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.02e-05	4.68e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EP300—attention deficit hyperactivity disorder	1.99e-05	4.6e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.97e-05	4.56e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.95e-05	4.5e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.95e-05	4.5e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EP300—attention deficit hyperactivity disorder	1.94e-05	4.49e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.94e-05	4.49e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.9e-05	4.4e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EP300—attention deficit hyperactivity disorder	1.9e-05	4.4e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	1.89e-05	4.38e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.88e-05	4.34e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EP300—attention deficit hyperactivity disorder	1.87e-05	4.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EP300—attention deficit hyperactivity disorder	1.86e-05	4.3e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.85e-05	4.27e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EP300—attention deficit hyperactivity disorder	1.84e-05	4.25e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EP300—attention deficit hyperactivity disorder	1.79e-05	4.15e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—EP300—attention deficit hyperactivity disorder	1.73e-05	4e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EP300—attention deficit hyperactivity disorder	1.72e-05	3.97e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.68e-05	3.89e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.67e-05	3.86e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.65e-05	3.81e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—EP300—attention deficit hyperactivity disorder	1.62e-05	3.74e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.56e-05	3.61e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—EP300—attention deficit hyperactivity disorder	1.56e-05	3.6e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	1.5e-05	3.46e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.5e-05	3.46e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—EP300—attention deficit hyperactivity disorder	1.49e-05	3.45e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	1.47e-05	3.4e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.47e-05	3.4e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.47e-05	3.4e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.46e-05	3.38e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—EP300—attention deficit hyperactivity disorder	1.44e-05	3.33e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—attention deficit hyperactivity disorder	1.38e-05	3.19e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.37e-05	3.16e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.29e-05	2.97e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—attention deficit hyperactivity disorder	1.27e-05	2.94e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.25e-05	2.9e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.23e-05	2.84e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.21e-05	2.8e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.2e-05	2.78e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.2e-05	2.77e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.14e-05	2.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.04e-05	2.42e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.01e-05	2.33e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	9.06e-06	2.1e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	9e-06	2.08e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.91e-06	2.06e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	6.31e-06	1.46e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	3.89e-06	8.99e-06	CbGpPWpGaD
